Agendia Appoints Patrick J. Balthrop Sr. as Chairman

Agendia, Inc. has announced the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.

"Patrick’s knowledge and experience in driving rapid growth in technology-led companies is exceptional, and will bolster Agendia’s position in the sector," said Mark R. Straley, CEO of Agendia. "Agendia is committed to improving the quality of life for cancer patients through molecular diagnostics, one patient at a time, and we are convinced that Patrick’s expertise will help us to achieve this. We warmly welcome him to the role of Chairman."

Agendia’s focuses on expanding the adoption of clinically genetic signatures as an aid to personalizing breast cancer treatment by increasing the geographic reach and reimbursement of these panels, such as MammaPrint 70-Gene Breast Cancer Risk-of-Recurrence Test.

Balthrop is currently a Director at Oxford Immunotec Global, Personalis, Inc. and Concert Genetics. He is an advisor to Water Street Healthcare Partners and the Founding Principal of investment and advisory firm, Apalachee Ventures. Balthrop previously held positions of CEO, President and Director at Luminex, and President at Fisher Healthcare.
Balthrop joins Christoph Waer (Korys), Jan Willem Nieuwenhuize (ING Corporate Investments), Erik Leeuwaarden (advisor), Peter Stein (Norgine) and Eric Esveld (Van Herk Groep) on the Board.